• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aerovate Therapeutics Inc (NQ: AVTE )

    1.967 -0.043 (-2.14%)
    Streaming Delayed Price Updated: 10:47 AM EDT, Jul 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Aerovate Therapeutics Inc

    Aerovate Therapeutics to Explore Strategic Alternatives
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
    AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses 
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
    Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in healthy adult participants 
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
    Adaptive and efficient trial design may allow for expedited development timeline while maintaining scientific rigor 
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.